Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1360-1364
Published online before print June 20, 2002, doi: 10.1161/01.ATV.0000027102.53875.47
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
22/8/1360    most recent
01.ATV.0000027102.53875.47v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakakibara, M.
Right arrow Articles by Handa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakakibara, M.
Right arrow Articles by Handa, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Pacemaker
Right arrow Pulmonary biology and circulation
Right arrow Smooth muscle proliferation and differentiation
Right arrow Other anticoagulants
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1360.)
© 2002 American Heart Association, Inc.

Thrombosis

Application of Ex Vivo Flow Chamber System for Assessment of Stent Thrombosis

Mamoru Sakakibara*; Shinya Goto*; Koji Eto; Noriko Tamura; Takaaki Isshiki; Shunnosuke Handa

From the Division of Cardiology, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan, and the Department of Medicine (T.I.), Teikyo University School of Medicine, Tokyo, Japan.

Correspondence to Shinya Goto, MD, Division of Cardiology, Department of Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1153, Japan. E-mail shinichi{at}is.icc.u-tokai.ac.jp


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— Factors influencing platelet accumulation around stents were to be investigated by an ex vivo flow chamber system.

Methods and Results— Platelet accumulations on collagen surfaces under flow conditions were augmented in the presence of stents, especially at sites downstream from coil stents. Densitometric analysis revealed that 4.9±0.8 times more platelets accumulated downstream from coil stents than were formed downstream from tube stents (P<0.01), suggesting that stent morphology is an important determinant factor of its thrombogenicity. Platelet accumulations around stents were significantly inhibited by a combination of ticlopidine and aspirin, whereas aspirin alone produced only modest inhibition. Anti–glycoprotein IIb/IIIa (abciximab) inhibited platelet accumulation around stents in a dose-dependent manner, whereas the antibody blocking von Willebrand factor binding to glycoprotein Ib{alpha}, which had been shown to inhibit platelet thrombus formation under high shear rates, did not inhibit the accumulation downstream from the coil stents. Our results suggest that the important characteristics of in vivo stent thrombosis, ie, augmented platelet accumulation with coil stents and the strong antithrombotic effect of the combination antiplatelet agents and an anti–glycoprotein IIb/IIIa, can be reproduced in ex vivo perfusion model.

Conclusions— We conclude that an ex vivo perfusion system is useful in the assessment of the thrombogenicity of various stents and in the screening of effective antiplatelet agents.


Key Words: stent thrombosis • platelets • glycoproteins • flow chamber • von Willebrand factor


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Coronary stent implantation is now an established procedure for the prevention of abrupt occlusion after unsuccessful coronary interventions.1 However, thrombotic occlusion of the coronary arteries2–4 (even though the incidence has been greatly reduced by high-pressure inflation and appropriate antithrombotic therapy)5 and restenosis occurring later in {approx}15% of patients6 are unresolved issues regarding the use of stents. The results of clinical trials have clearly demonstrated that therapy with antiplatelet drugs, a combination of aspirin and ticlopidine, was more effective than persistent powerful anticoagulation with an oral anticoagulant,3–5,7 suggesting an important role of platelets in the onset of stent thrombosis. Platelet accumulation around the stent is also believed to play a role in the later event of restenosis via local release of bioactive materials, such as platelet-derived growth factor8,9 or recruitment of leukocytes,10 although there are, as yet, no convincing clinical data showing the effects of antiplatelet agents on restenosis.11 Nevertheless, it is reasonable to speculate that inhibition of the platelet accumulation around stents would facilitate reducing not only acute vascular events but also the subsequent event, restenosis. Indeed, clinical experiences and animal experiments have suggested that patient factors,12 vascular factors (such as small vessel diameter),13 and stent factors (such as the shape of the stent)14,15 may affect platelet accumulation, thus influencing the rate of restenosis.

In the present study, we constructed a flow chamber equipped with an epifluorescence videomicroscope. This device enabled us to visualize platelet thrombus formation on collagen surfaces under flow conditions. We attempted to clarify the effects of stent morphology, stent thickness, and the type of metal used on platelet accumulation around the stent by comparing the thrombogenicity of several stents having different characteristics. To test the validity of our assay system, we tested in an ex vivo flow chamber system the effects of antiplatelet therapy known to be effective for preventing platelet thrombosis, such as anti–glycoprotein (GP) II/b/IIIa agents16,17 and a combination of aspirin and ticlopidine, 3 or less effective therapy, such as aspirin alone.7 We also tested the effects of the agent known to block von Willebrand factor (VWF) binding to platelet GP Ib{alpha}, which was reported to play crucial roles in platelet thrombus formation at sites exposed to high shear stress,18–22 on platelet accumulation around stents.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Preparation of Blood Samples
Blood samples were collected from healthy adult donors after obtaining written informed consent. All the donors were requested to abstain from using drugs known to interfere with platelet function, such as aspirin, for at least 1 month before the blood collection. Blood samples were drawn from the antecubital vein with the use of 19-gauge needles and immediately transferred to plastic tubes containing 1/10 of their volume of the specific thrombin inhibitor, Argatroban (Mitsubishi Kagaku). To test the effects of aspirin and the combination of aspirin plus ticlopidine, additional blood samples were collected 10 hours after oral intake of aspirin (500 mg/d) and 10 hours after oral intake of aspirin subsequent to the 1-week consecutive oral intake of ticlopidine (200 mg/d). Argatroban, instead of the common anticoagulant citrate, at a final concentration of 100 µmol/L was used for anticoagulation of the blood22,23 in performing experiments in the presence of the physiological concentrations of divalent cations because the biological function of GP IIb/IIIa was known to be influenced by divalent cation concentrations.24,25 We did not choose heparin as an anticoagulant, even though it is commonly used in patients undergoing interventional treatment, because that anticoagulant, having various pleiotropic effects on platelet functions, is not a pure material.26

Platelets were rendered fluorescent by the addition of mepacrine at a final concentration of 10 µmol/L (Sigma Chemical Co). Although mepacrine is known to affect platelet function through the inhibition of phospholipid hydrolysis,27 that effect can be negligible at the dose that we used.23,28,29

Preparation of Flow Chamber System and Platelet Thrombus Visualization by Epifluorescence Videomicroscopy
A Hele-Shaw type of flow chamber with immobilized type I collagen was prepared as described previously.23,28–30 Then, the blood samples were aspirated through the chamber with a syringe pump (Holliston, MA 01746, Harvard Apparatus) at a constant flow rate to achieve a wall shear rate on the collagen surface of 1500 s-1 in the absence of the stent.23 To generate pulsatile flow conditions, blood flow was stopped for 1 minute after every 1 minute of perfusion. Note that the wall shear rate cannot even be roughly estimated in the presence of a stent because the local flow environment is randomly disturbed by the presence of stents.

The effects of these stents with different characteristics, as described below, on platelet thrombus formation were evaluated. The Palmaz-Schatz stent, a typical slotted tube stent with different metal thicknesses (PS14, thickness 0.635 mm; PS15, thickness 1.01 mm; Johnson & Johnson), and GFX and Wiktor stents (Medtronic), typical coil stents, were inflated with a balloon to a pressure of 7 atm. Parts of the stents were then cut and placed on the collagen-coated glass coverslips and tightly pushed to be fixed on the collagen surface as demonstrated in Figure 1. Because the flow route was exactly 2.2 mm in width, only pairs of struts could be placed. Larger parts of the PS15 and GFX stents were cut and placed in the proximal portion in the Hele-Shaw chamber, which has wider flow routes.30 Note that the blood flow rate should be increased by a factor of 3 to assess the levels of thrombogenicity of the larger parts of stents in the same wall shear rate condition as in the absence of stents and that only a shorter period of blood perfusion (2 minutes) was available with the limited amount of fresh blood obtainable from blood donors. Platelet thrombi forming on the collagen surface in the presence and absence of various stents were visualized by using an epifluorescence videomicroscope system (DM IRB, 1RB-FLUO, Leica). The microscopic images were digitized online with a photosensitive color CCD camera (L-600, Leica) and stored as digital images in a personal computer (Power Macintosh G3, Apple, Co, Ltd). For quantitative analysis, digital color images were converted to 256 scales of gray-scale images by using NIH image (version 1.62, public domain software by Dr Wayne Rasband, National Institutes of Health). Then, the regions of interest (ROIs) were set to calculate the mean gray-scale number, which corresponded to the number of platelets deposited, in the areas described in the Figure 1 legend.



View larger version (55K):
[in this window]
[in a new window]
  		Figure 1. Visualization of platelet thrombus formation around a stent. Blood containing fluorescein-labeled platelets was perfused into a flow chamber. One of the various stents described in Methods was expanded, cut, and tightly fixed on the collagen surface, in the same direction as would have been placed in coronary arteries, in the flow chamber system, as shown on the top right. The positions of the stents on the collagen surface in the chamber were detected by using an inverted stage microscope before blood perfusion, as demonstrated on the bottom left. For quantitative densitometric analysis of platelet deposition, the rectangular ROI numbers from 1 to 3 were set to calculate mean gray-scale values, representing the amount of platelet accumulation in the area. Rectangles 1 and 3 indicate the positions of ROIs placed upstream and downstream from stents, respectively. The amount of platelet accumulation in the space between the stent and the collagen surface was estimated by calculating the mean gray scales in ROI 2.

Monoclonal Antibodies and Antiplatelet Agents Used for Functional Inhibition of Platelet Receptors
The murine monoclonal antibody against GP Ib{alpha} (LJ-Ib1) was kindly provided by Dr Zaverio M. Ruggeri of the Scripps Research Institute (La Jolla, Calif) and has previously been shown to inhibit VWF–GP Ib{alpha} interaction under all experimental conditions tested.31 Abciximab was used as an anti–GP IIb/IIIa agent, which blocks the binding of plasma ligands such as fibrinogen and VWF to GP IIb/IIIa.32,33 Recent clinical investigations have revealed abciximab to be effective in preventing acute thrombotic occlusion of the coronary arteries after interventional treatment34 and stent implantation.5,16,17

Statistical Analysis
The arbitrary gray-scale values in each ROI are expressed as mean±SD unless otherwise specified. The differences between the mean gray-scale values of the different sites in the same experiments were evaluated by the Student paired t test. The mean gray scales in the absence and presence of various stents were compared by the Student unpaired t test. A value of P<0.05 was considered statistically significant.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
Platelet Accumulations on Collagen Surfaces in Presence or Absence of Stents
Platelets adhered to the collagen surface and formed thrombi in the presence and absence of stents (please see Figure I, available online at http://atvb.ahajournals.org). However, more platelet deposition was demonstrated in the presence of either the typical Palmaz-Schatz tube stent (PS14 and PS15) or the typical GFX and Wiktor coil stents, the distributions of which were not similar. Indeed, significant platelet accumulation downstream from the stent, in addition to the accumulation in the space between stents and collagen, was demonstrated in the presence of coil stents but not in the presence of tube stents. No significant platelet accumulation was detected when the glass coverslip was not covered with collagen even in the presence of stents (data not shown).

Stent Characteristics Related to Thrombogenicity
As shown in online Figure I and Figure 2, there were no significant differences in the amounts of platelets accumulated around PS14 and PS15, stents with the same metallic component and similar shapes but with different thicknesses of metal, suggesting that the thickness of the metallic component of the stent is not a major determinant of their thrombogenicity. Densitometric analysis revealed that 4.9±0.8 and 4.2±1.2 times more platelets accumulated on the collagen surface downstream than upstream from the respective GFX and Wiktor coil stents, which had different metallic components (both P<0.01). These different distributions were not found with tube stents. Significant platelet accumulation was noted downstream from coil stents, but not tube stents, when the blood flow became pulsatile (data not shown) or when larger parts of multiple struts were placed (please see Figure II, available online at http://atvb.ahajournals.org).



View larger version (30K):
[in this window]
[in a new window]
  		Figure 2. Densitometric analysis of platelet deposition on the surface of collagen in the presence of various stents. After the color images were converted to 256 scales of gray-scale images, ROIs, the sizes of which were 360 square pixels each, were set to calculate the mean number of gray scales in the areas, as indicated in Figure 1. Upstream and downstream indicate the gray-scale value upstream and downstream from each of the stents (corresponding to ROIs 1 and 3, as described in the Figure 1 legend); in between, the gray-scale value corresponding to platelet accumulation in the space between the stent and the collagen surface (corresponding to ROI 2, as described in the Figure 1 legend). Details are presented in Results. Data are mean±SD of the 6 experiments performed.

Effects of Monoclonal Antibodies and Antiplatelet Agents
As shown in Figure III (available online at http://atvb. ahajournals.org), abciximab inhibited platelet thrombus formation around GFX stents in a dose-dependent manner. Platelet thrombus formation was completely inhibited at a dose of 2 µg/mL. Similar dose-dependent inhibition was seen with the PS15 stent (data not shown). A specific anti–GP Ib{alpha} antibody, LJ-Ib1, at a concentration enough to inhibit all available platelet surface GP Ib{alpha}, abolished platelet deposition on the collagen surface around the stents, especially at the upper reaches of flow (Figure 3). However, LJ-Ib1 did not inhibit platelet thrombus formation in the spaces between the stent and the collagen surface and platelet accumulation downstream from the coil stents. Figure 4 demonstrates the effects of commonly used antiplatelet agents on platelet accumulation around the stents. In agreement with previously published clinical experience,3,7 a combination of aspirin and ticlopidine strongly inhibited platelet accumulation around the stents (regardless of whether they were tube or coil), whereas aspirin alone showed only modest inhibition.



View larger version (30K):
[in this window]
[in a new window]
  		Figure 3. Densitometric analysis of the effects of function-blocking monoclonal antibodies on platelet thrombus formation. Experiments were performed in a manner similar to that described in online Figure I and Figure 2 legends, but blood containing chimeric monoclonal antibody blocking GP IIb/IIIa (final concentration, 10 µg/mL abciximab) or LJ-Ib1 antibody blocking VWF-GP Ib{alpha} interaction (final concentration 200 µg/mL) was perfused. The former shows homogeneous inhibition; the later shows the site-specific inhibition, ie, no inhibition on the collagen surface downstream from the GFX stent. The same was true for the Wiktor stent (data not shown). Densitometric analysis was performed as described in the Figure 2 legend. Data are mean±SD of the 6 experiments.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 4. Densitometric analysis of the effects of oral intake of aspirin and ticlopidine on platelet accumulation around stents. Experiments were performed in a manner similar to that described in online Figure I and Figure 2 legends, but the blood obtained from donors before and after the oral intake of aspirin or a combination of aspirin and ticlopidine, as described in Methods, was perfused. Densitometric analysis was performed as described in the Figure 2 legend. Data are mean±SD of the 6 experiments.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
Our results demonstrate that platelet thrombus formation on collagen surfaces under flow conditions is enhanced by the presence of stents, especially coil stents, the placement of which is associated with a higher risk of thrombotic occlusion35 and angiographically determined restenosis in vivo.14,36,37 Our results also show that ex vivo chamber systems demonstrate antithrombotic effects similar to those of antiplatelet agents used in vivo, ie, similar to the superior effects of the combination of aspirin and ticlopidine rather than aspirin alone.3,7 Those results (along with the finding that the inhibiting effects of abciximab on platelet accumulation around a stent in an ex vivo flow chamber system were achieved at a dose previously shown to be effective for preventing vascular complications after stent implantation in vivo)5,16 also suggest that the in vivo antithrombotic effects may be predicted by an ex vivo perfusion system.

Nevertheless, there are limitations to the methodology used in our experiments, particularly regarding the application of our ex vivo results to the understanding of events occurring in clinical situations. Obviously, we cannot perfectly reproduce in our flow chamber system the complex in vivo flow conditions prevailing around stents implanted in coronary arteries. For example, the significant platelet accumulations in the space between the stents and the collagen surface, regardless of the type of stents observed in our experiments, might not be clinically relevant, because there should be no such space when the stent expands to fit within the soft vascular tissue in the coronary arteries. As demonstrated in Figure 2 through Figure 4 (and also online Figure I through Figure III), platelets slip into the space between the stents and collagen, although we attempted to minimize the space by tightly pushing the stents onto the collagen surface before starting blood perfusion. We could not quantify the space generated by platelet migration, but a quantitative comparison shown by Figure 2 suggested that variations in the dimensions or effects of these spaces were not markedly different from experiment to experiment because the standard errors of platelet accumulation in the spaces between collagen and stents are similar to the values of those accumulated upstream and downstream from the stents. We speculate that the space between stents and collagen may not influence our findings regarding platelet accumulation upstream and downstream from the stents or the effects of antiplatelet agents because the variations in the spaces were minimized by our experimental setting. Moreover, in vivo pulsatile flow conditions can hardly be reproduced in our flow chamber system. As previously demonstrated,38 not only the extent of platelet thrombus formation but also the underlying mechanisms involved might be different under the pulsatile flow condition. Although we have experimentally concluded that the significant accumulation observed downstream from coil stents was not influenced even by the changing shear rates generated by the stop and flow conditions, our experimental conditions were indeed far different from the complex flow conditions actually prevailing in the coronary arteries.

Methodologically, there is another important limitation to our flow chamber experiments; ie, the 2 potentially important factors, thrombin and fibrin formation,39 could not be considered in the presence of an anticoagulant, although we attempted to minimize the influences of the anticoagulant by using the reversible thrombin inhibitor Argatroban, as mentioned in Methods. One might also claim that the effects of only parts of stents, and not entire stents, could be assessed in our system. Although we have shown that the significant accumulation of platelets downstream from the coil stents that we observed with single strut placement was not changed even in the presence of larger parts of multiple struts, our assay system has many limitations in assessing the larger parts of stents. We could conduct the experiments with only the larger parts of stents within a shorter period of blood perfusion (2 minutes), although the degrees of reproducibility of the results become poorer with shorter perfusion periods. In spite of all the above limitations, however, we would still like to emphasize that the ex vivo system, if reflecting certain important in vivo characteristics of stent thrombosis, will be useful for screening less thrombogenic stents and developing better adjuvant therapy before conducting expensive clinical trials.

Our experiments demonstrate that compared with aspirin alone, a combination of aspirin and ticlopidine is more effective in preventing platelet accumulation around stents. Because platelet attachment on the collagen surface was mediated by its binding to VWF attached on collagen and collagen itself,29 blocking the interaction between VWF and its corresponding receptor GP Ib{alpha} alone was not sufficient to inhibit platelet accumulation around stents. Strong antithrombotic effects of the combination of aspirin and P2Y12 inhibition40 might be explained by the synergistic effects of cyclooxygenase inhibition by aspirin (which has previously been reported to inhibit collagen-induced41 but not VWF-induced42 platelet activation) and P2Y12 inhibition by ticlopidine (which has been shown to be effective on collagen-induced43 and VWF-induced42 platelet activation). An ex vivo flow chamber system may be a better tool for assessing combination drug therapy than conventional agonist-induced platelet aggregation, because multiple synergistic stimulations initiated from various receptors are involved.29

In conclusion, we applied an ex vivo flow chamber system to assess factors influencing stent thrombosis, and we found it useful for screening stents less thrombogenic and for screening the antiplatelet agents effective for stent thrombosis.


*    Acknowledgments
 
This work was supported in part by a grant-in-aid for Scientific Research in Japan (NO. 13670744), by grant JSPS-RFTF97I00201 from the Japanese Society for the Promotion of Science, by a grant from the Science Frontier Program of MESSC of Japan, by a research fund of the Japan Foundation of Cardiovascular Research in 2001, and by the Suzuken Memorial Fund 1999.


*    Footnotes
 
*These authors contributed equally to the present study. Back

Received November 6, 2001; accepted May 28, 2002.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Fischman DL, Leion MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331: 489–495.[Abstract/Free Full Text]
  2. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy JJ, Vogt P, Kappenberger L, Sigwart U. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med. 1991; 324: 13–17.[Abstract]
  3. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084–1089.[Abstract/Free Full Text]
  4. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98: 2126–2132.[Abstract/Free Full Text]
  5. Harding SA, Walters DL, Palacios IF, Oesterle SN. Adjunctive pharmacotherapy for coronary stenting. Curr Opin Cardiol. 2001; 16: 293–299.[CrossRef][Medline] [Order article via Infotrieve]
  6. Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty: Restenosis Stent Study Group. N Engl J Med. 1998; 339: 1672–1678.[Abstract/Free Full Text]
  7. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339: 1665–1671.[Abstract/Free Full Text]
  8. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992; 89: 507–511.
  9. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991; 253: 1129–1132.[Abstract/Free Full Text]
  10. Springer TA. Adhesion receptors of the immune system. Nature. 1990; 346: 425–434.[CrossRef][Medline] [Order article via Infotrieve]
  11. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000; 35: 915–921.[Abstract/Free Full Text]
  12. Mehilli J, Kastrati A, Dirschinger J, Bollwein H, Neumann FJ, Schomig A. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA. 2000; 284: 1799–1805.[Abstract/Free Full Text]
  13. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation. 1998; 98: 1875–1880.[Abstract/Free Full Text]
  14. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995; 91: 2995–3001.[Abstract/Free Full Text]
  15. Kastrati A, Schomig A, Dirschinger J, Mehilli J, von Welser N, Pache J, Schuhlen H, Schilling T, Schmitt C, Neumann FJ. Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation. 2000; 101: 2478–2483.[Abstract/Free Full Text]
  16. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial: EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999; 354: 2019–2024.[CrossRef][Medline] [Order article via Infotrieve]
  17. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000; 356: 2037–2044.[CrossRef][Medline] [Order article via Infotrieve]
  18. Goto S, Handa S. Coronary thrombosis: effects of blood flow on the mechanism of thrombus formation. Jpn Heart J. 1998; 39: 579–596.[Medline] [Order article via Infotrieve]
  19. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996; 88: 1525–1541.[Free Full Text]
  20. Bellinger DA, Nichols TC, Read MS, Reddick RL, Lamb MA, Brinkhous KM, Evatt BL, Griggs TR. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A. 1987; 84: 8100–8104.[Abstract/Free Full Text]
  21. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as consequence of different shearing flow conditions. J Clin Invest. 1998; 101: 479–486.[Medline] [Order article via Infotrieve]
  22. Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood. 1999; 94: 968–975.[Abstract/Free Full Text]
  23. Eto K, Goto S, Shimazaki T, Yoshida M, Sakakibara M, Isshiki T, Handa S. Two distinct mechanisms are involved in stent thrombosis under flow conditions. Platelets. 2001; 12: 228–235.[CrossRef][Medline] [Order article via Infotrieve]
  24. Marciniak SJ Jr, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost. 2001; 85: 539–543.[Medline] [Order article via Infotrieve]
  25. Bajt ML, Loftus JC. Mutation of a ligand binding domain of beta 3 integrin: integral role of oxygenated residues in alpha IIb beta 3 (GPIIb-IIIa) receptor function. J Biol Chem. 1994; 269: 20913–20919.[Abstract/Free Full Text]
  26. Kawano K, Ikeda Y, Handa M, Kamata T, Anbo H, Araki Y, Kawai Y, Watanabe K, Itagaki I, Kawakami K, Sakai H. Enhancing effect by heparin on shear-induced platelet aggregation. Semin Thromb Hemost. 1990; 16 (suppl): 60–65.
  27. Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemost. 1981; 45: 257–262.[Medline] [Order article via Infotrieve]
  28. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84: 289–297.[CrossRef][Medline] [Order article via Infotrieve]
  29. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998; 94: 657–666.[CrossRef][Medline] [Order article via Infotrieve]
  30. Usami S, Chen HH, Zhao Y, Chien S, Skalak R. Design and construction of a linear shear stress flow chamber. Ann Biomed Eng. 1993; 21: 77–83.[CrossRef][Medline] [Order article via Infotrieve]
  31. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem. 1995; 270: 23352–23361.[Abstract/Free Full Text]
  32. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985; 76: 101–108.
  33. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983; 72: 325–338.
  34. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336: 1689–1696.[Abstract/Free Full Text]
  35. Anzuini A, Rosanio S, Legrand V, Tocchi M, Coppi R, Bonnier H, Sheiban I, Kulbertus HE, Chierchia SL. Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience. J Am Coll Cardiol. 1998; 31: 281–288.[Abstract/Free Full Text]
  36. Escaned J, Goicolea J, Alfonso F, Perez-Vizcayno MJ, Hernandez R, Fernandez-Ortiz A, Banuelos C, Macaya C. Propensity and mechanisms of restenosis in different coronary stent designs: complementary value of the analysis of the luminal gain-loss relationship. J Am Coll Cardiol. 1999; 34: 1490–1407.[Abstract/Free Full Text]
  37. Yoshitomi Y, Kojima S, Yano M, Sugi T, Matsumoto Y, Saotome M, Tanaka K, Endo M, Kuramochi M. Does stent design affect probability of restenosis?: a randomized trial comparing Multilink stents with GFX stents. Am Heart J. 2001; 142: 445–451.[CrossRef][Medline] [Order article via Infotrieve]
  38. Merten M, Chow T, Hellums JD, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation. 2000; 102: 2045–2050.[Abstract/Free Full Text]
  39. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation. 1998; 98: 224–233.[Abstract/Free Full Text]
  40. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409: 202–2027.[CrossRef][Medline] [Order article via Infotrieve]
  41. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994; 83: 885–898.[Free Full Text]
  42. Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, Itagaki I. Shear-induced platelet aggregation in cerebral ischemia. Stroke. 1994; 25: 1547–1551.[Abstract]
  43. Savi P, Herbert JM. Pharmacology of ticlopidine and clopidogrel. Haematologica. 2000; 85: 73–77.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Aktas, M. Pozgajova, W. Bergmeier, S. Sunnarborg, S. Offermanns, D. Lee, D. D. Wagner, and B. Nieswandt
Aspirin Induces Platelet Receptor Shedding via ADAM17 (TACE)
J. Biol. Chem., December 2, 2005; 280(48): 39716 - 39722.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. Hafezi-Moghadam, K. L. Thomas, and C. Cornelssen
A novel mouse-driven ex vivo flow chamber for the study of leukocyte and platelet function
Am J Physiol Cell Physiol, April 1, 2004; 286(4): C876 - C892.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
22/8/1360    most recent
01.ATV.0000027102.53875.47v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakakibara, M.
Right arrow Articles by Handa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakakibara, M.
Right arrow Articles by Handa, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Pacemaker
Right arrow Pulmonary biology and circulation
Right arrow Smooth muscle proliferation and differentiation
Right arrow Other anticoagulants

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.